JP2020530978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530978A5 JP2020530978A5 JP2019570859A JP2019570859A JP2020530978A5 JP 2020530978 A5 JP2020530978 A5 JP 2020530978A5 JP 2019570859 A JP2019570859 A JP 2019570859A JP 2019570859 A JP2019570859 A JP 2019570859A JP 2020530978 A5 JP2020530978 A5 JP 2020530978A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- protein
- primer
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 7
- 108010024164 HLA-G Antigens Proteins 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108091092195 Intron Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305986.6A EP3434688A1 (en) | 2017-07-24 | 2017-07-24 | Hla-g transcripts and isoforms and their uses |
| EP17305986.6 | 2017-07-24 | ||
| PCT/EP2018/070061 WO2019020641A1 (en) | 2017-07-24 | 2018-07-24 | TRANSCRIPTS AND ISOFORMS OF HLA-G AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530978A JP2020530978A (ja) | 2020-11-05 |
| JP2020530978A5 true JP2020530978A5 (enExample) | 2021-09-02 |
| JP7271446B2 JP7271446B2 (ja) | 2023-05-11 |
Family
ID=59772544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570859A Active JP7271446B2 (ja) | 2017-07-24 | 2018-07-24 | Ｈｌａ－ｇ転写物およびアイソフォームおよびそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11655283B2 (enExample) |
| EP (2) | EP3434688A1 (enExample) |
| JP (1) | JP7271446B2 (enExample) |
| CN (1) | CN110799530A (enExample) |
| WO (1) | WO2019020641A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113528448B (zh) * | 2020-04-14 | 2023-01-24 | 同济大学 | 一种人胚胎干细胞的构建方法 |
| CN113278590A (zh) * | 2021-04-23 | 2021-08-20 | 台州恩泽医疗中心(集团) | 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用 |
| CN113249329A (zh) * | 2021-04-23 | 2021-08-13 | 台州恩泽医疗中心(集团) | 表达α1结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用 |
| GB202111905D0 (en) * | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| AU2023238458A1 (en) * | 2022-03-25 | 2024-10-17 | Hk Inno.N Corporation | Hla-g-specific antibody and use thereof |
| WO2025101877A1 (en) * | 2023-11-08 | 2025-05-15 | The Children's Hospital Of Philadelphia | Platform for increasing hla class i antigen presentation utilizing engineered chaperone fusion proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2510895A1 (en) * | 2002-12-20 | 2004-07-15 | Applera Corporation | Genetic polymorphisms associated with stenosis, methods of detection and uses thereof |
| FR2856599A1 (fr) * | 2003-06-30 | 2004-12-31 | Commissariat Energie Atomique | Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang. |
| WO2007091078A2 (en) * | 2006-02-10 | 2007-08-16 | Axordia Limited | Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g |
| EP2730588A1 (en) * | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| US10702559B2 (en) * | 2016-02-09 | 2020-07-07 | The General Hospital Corporation | Methods and compositions relating to engineered microbial cells |
-
2017
- 2017-07-24 EP EP17305986.6A patent/EP3434688A1/en not_active Withdrawn
-
2018
- 2018-07-24 WO PCT/EP2018/070061 patent/WO2019020641A1/en not_active Ceased
- 2018-07-24 US US16/625,254 patent/US11655283B2/en active Active
- 2018-07-24 JP JP2019570859A patent/JP7271446B2/ja active Active
- 2018-07-24 CN CN201880041616.XA patent/CN110799530A/zh active Pending
- 2018-07-24 EP EP18743527.6A patent/EP3658579A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530978A5 (enExample) | ||
| JP2014239695A5 (enExample) | ||
| Bijkerk et al. | Hematopoietic microRNA-126 protects against renal ischemia/reperfusion injury by promoting vascular integrity | |
| Pinto et al. | CiC3-1a-mediated chemotaxis in the deuterostome invertebrate Ciona intestinalis (Urochordata) | |
| JP2011523550A5 (enExample) | ||
| JP2017537919A5 (enExample) | ||
| Jagessar et al. | Lymphocryptovirus infection of nonhuman primate B cells converts destructive into productive processing of the pathogenic CD8 T cell epitope in myelin oligodendrocyte glycoprotein | |
| FI3294333T4 (fi) | Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit | |
| JP2016516735A5 (enExample) | ||
| JP2018535647A5 (enExample) | ||
| JP2020534828A5 (enExample) | ||
| FI3256579T3 (fi) | Kysteiiniproteaasi | |
| US11352389B2 (en) | Treatment of haematological malignancies | |
| JP2013524792A5 (enExample) | ||
| SG10201802281XA (en) | Assay For The Diagnosis Of Dermatophytosis | |
| WO2013130499A1 (en) | Compositions and methods for cxcr4 signaling and umbilical cord blood stem cell engraftment | |
| JP2014533098A5 (enExample) | ||
| US20220305102A1 (en) | Treatment of haematological malignancies | |
| KR102569494B1 (ko) | Cd44의 단리된 폴리펩타이드 및 이의 사용 | |
| JP2009525741A5 (ja) | HERV−W干渉群に属するウィルスの包膜とhASCT受容体との間の相互作用に必要なペプチド領域からなるペプチド | |
| Del Papa et al. | Anti-endothelial cell antibodies and autoimmune diseases | |
| JP2016520570A (ja) | Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト | |
| Mignane et al. | Modulation of monocyte subsets in infectious diseases | |
| Middleton et al. | Resistance Profile Of ABT-333 And Relationship To Viral Load Decrease In Patients Treated In Combination With Peg-interferon And Ribavirin For 28 Days. | |
| Venturini et al. | Altered distribution of peripheral blood dendritic cell subsets in patients with pulmonary paracoccidioidomycosis |